National program for Clinical Treatment Research in the Specialist Health Service (KLINBEFORSK)
- Project: PANORAMIC Norway - Interventions against long COVID in Norway (2022-2025)
- Project Owner: Haukeland University Hospital
- Total Budget: 20 million NOK
- Research Group Funding: 12.9 million NOK
EU Innovative Health Initiative (IHI)
- Project: Inno4Vac - Innovations to accelerate vaccine development and manufacture (2021-2026)
- Project Owner: European Vaccine Initiative (EVI)
- Total Budget: €18.6 million
- Research Group Funding: €752,594 (Work Package lead for development of an improved influenza human challenge model)
Horizon 2020 EU's research and innovation funding programme (H2020)
- Project: VACCELERATE - European Corona Vaccine Trial Accelerator Platform (2021-2025)
- Project Owner: University of Cologne, Germany
- Total Budget: €12 million
- Research Group Funding: €661,033 (National Coordinator and Work Package leader)
The Research Council of Norway (RCN), TMF, Western Norway Regional Health authority (Helse Vest RHF)
- Project: COVID-19 in healthcare workers and the general population in Western Norway (2020-2024)
- Project Owner: University of Bergen, Haukeland University Hospital
- Research Group Funding: 11.2 million NOK
Trond Mohn Foundation
- Project: COVID-19 infection in healthcare workers and the general population (2020-2022)
NORCE Research
- Project: MONCOVID-19: Technologies for Monitoring COVID-19 Epidemiological Development (2020-2022)
- Project Link / Website: MONCOVID-19 Project
Helse Vest
- Project: Research into COVID-19 Infection in Bergen: The Clinical and Immune Response in Healthcare Workers and the General Population (2020-2021)
- Project Number: F-11628
EU Innovative Medicines Initiative (IMI)
- Project: FLUCOP - Standardisation and development of assays for assessment of influenza vaccine correlates of protection (2015-2020)
- Project Owner: SANOFI PASTEUR SA
- Total Budget: €13.85 million
- Research Group Funding: €697,000
EU Nanomedicines (2017-2021)
- Project: Design of Human Influenza vaccines using multifunctional micelles harnessing innate immunity
- Partners: Centre National de la Recherche Scientifique (CNRS), France; Fundació Clínic per la Recerca Biomèdica (FCRB) - Hospital Clinic de Barcelona (HCB), Spain; ADJUVATIS, France; Commissariat à l’Energie Atomique IDMIT, France; University of Bergen
RCN Norwegian Research School in Infection Biology and Antimicrobials (IBA) (2016-2020)
- Partners: University of Oslo, University of Tromsø, Norwegian University of Life Sciences, Norwegian University of Science and Technology, University of Bergen, Faculty of Medicine Umeå University, Sweden, University of Copenhagen, Denmark
- Total budget: 23.8 million kroner
K.G. Jebsen Centre for Influenza Vaccine Research (2013-2019)
- Partners: University of Oslo, Oslo University Hospital, The Norwegian Institute of Public Health, University of Bergen
- Total budget: 20 million kr
EU FP7 Univax (2013-2018)
- Project: A “Universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines
- Partners: Switzerland, France, Russian Federation, Germany, Czech Republic, UK, Norway
- Total budget: €6 million
- Project Link / Website: EU FP7 Univax Project
RCN Globvac (2013-2017)
- Project: Improved childhood vaccination and preparedness against seasonal and pandemic influenza: prospects for cellular immunity
- Partners: Norway (The Norwegian Institute of Public Health, University of Bergen), USA, Hungary, Bangladesh, and Ethiopia
RCN Biobank (2013-2017)
- Project: Perinatal outcomes and children’s health after prenatal exposure to influenza and influenza vaccination
- Partners: Norway (The Norwegian Institute of Public Health, University of Bergen), USA (Columbia University, La Jolla Institute of Allergy and Immunology)
Helse Vest Influenza A(H7) Studies (2014-2016)
- Partners: University of Bergen, Health Protection England, UK; University of Oxford, UK; Mount Sinai USA
RCN Globvac (2008-2012)
- Project: The immunogenicity & protective efficacy of plant-derived influenza H5N1 vaccine in preclinical models
- Partners: UK, Germany, USA, and Norway
EU FP7 NASPANVAC (2008-2012)
- Project: Intranasal pandemic influenza vaccine
- Partners: UK, Ireland, Italy, and Norway
EU FP6 Panfluvac (2007-2011)
- Project: Efficacious vaccine formulation system for prophylactic control of influenza pandemics
- Partners: Switzerland, UK, Germany, Italy, and Norway
EU FP5 FLUPAN (2001-2006)
- Project: Preparing for an influenza pandemic
- Partners: UK, France, Italy, and Norway
EU FP 4 (1996-1999)
- Project: Genetic and immunological safety of DNA vaccines
- Partners: UK, Ireland, Spain, and Norway
Norwegian